WANY
ABCL icon

Wealthspire Advisors (New York)’s AbCellera Biologics ABCL Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-790
Closed -$3.97K – 1039
2025
Q3 		$3.97K Buy
+790
New +$3.48K ﹤0.01% 2409

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthspire Advisors (New York)'s ABCL Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 790 shares — an estimated $3.97K sold.

Wealthspire Advisors (New York) first reported a position in ABCL in Q3 2025 and held it in 1 quarter. The position peaked at $3.97K in Q3 2025. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 790 AbCellera Biologics shares in Q4 2025, an estimated $3.97K.
  • Wealthspire Advisors (New York) first reported a position in AbCellera Biologics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s AbCellera Biologics position peaked at $3.97K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.